snow
Events - Slide 1 Events - Slide 2 Events - Slide 3 Events - Slide 4

Welcome to Retina Specialists Northwest

Dedicated to delivering compassionate excellence in retinal and inflammatory eye disease always.

Retina Specialists Northwest, PLLC is an ophthalmic subspecialty practice focused on Retina and Uveitis. The practice philosophy is summarized in the company motto: Compassionate Excellence Always.

Board certified eye physician and surgeon, Dr. Brenda Myers-Powell

Dr. Myers-Powell and her staff are committed to delivering the best in personalized retinal care efficiently and effectively. Our pledge is to understand you as a whole and to provide the best available medical and surgical treatment tailored to your needs. We are centrally located between Seattle and Tacoma, at West Campus in Federal Way, strategically positioned to deliver quality care to residents within and outside the metropolitan areas. Our office is easily accessible from I-5, Hwy-18, Hwy-167, and Hwy-99. For your convenience, we are open most Saturdays.

We utilize the latest technology as well as clinical expertise to diagnose and manage all retinal and inflammatory disorders with particular attention to Retinal Tear and Detachment, Disorders of the Vitreous, Macular Holes, Diabetic Retinopathy, Age-related Macular Degeneration, Retinal Vascular Disease, Macular Edema, Scleritis, and vision-threatening Uveitis.

Ultra-Widefield Multifocal Electroretinography and Visual Evoked Potentials

Retina Specialists Northwest is proud to announce the implementation of Diagnosys Ultra-Widefield Multifocal Electroretinography (mfERG) and Visual Evoked Potentials (VEP) as part of our service. This diagnostic tool can significantly benefit those with retinal and optic nerve disease.

Retina Specialists Northwest has invested in elevating the level of care in the Puget Sound area by providing a valuable service that had previously been unavailable in our community.

The mfERG can objectively assess cone dysfunction and macular disease facilitating diagnosis and assessment of progression of macular disorders such as Retinal Dystrophy, ARMD, Diabetic Retinopathy and Drug Toxicity. The AAO has listed mfERG as a critical test modality for screening for Plaquenil Toxicity.

VEP can assess optic nerve function, improving the diagnosis and management of Optic Neuritis and Optic Neuropathy. This is particularly useful in Multiple Sclerosis.

Our Federal Way office will provide this service at your patients' convenience.

Call (253) 517-3334 to schedule an appointment.

News from NEI

Two NEI Grantees Awarded Helen Keller Prize

Two researchers funded by the National Eye Institute (NEI), both pioneers in the study of low vision, received the Helen Keller Prize for Vision Research on May 5, in Denver. The Helen Keller Foundation for Research and Education, and BrightFocus Foundation, presented the award to Gordon E.

05/13/15 5:46 am

Early Tight Blood Glucose Control Reduces Eye Surgeries in People with Type 1 Diabetes

People with type 1 diabetes who intensively control their blood glucose (blood sugar) early in their disease, versus those who do not, are 48 percent less likely to need eye surgery, and the total number of such surgeries is 37 percent less.

05/08/15 10:16 am

NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy

Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes vision loss starting in childhood, improved patients’ eyesight and the sensitivity of the retina within weeks of treatment. Both of these benefits, however, peaked one to three years after treatment and then diminished, according to results from an ongoing clinical trial funded by the National Eye Institute (NEI), part of the National Institutes of Health.

English

05/01/15 8:13 am

NIH Launches Research to Gaze Deeply Into Your Eyes

Five bold projects will develop new technology to noninvasively image cells of the eye in unprecedented detail. The National Eye Institute (NEI) announced the awards as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.

English

04/30/15 7:40 am

NEI Human Gene Therapy Trial for Retinoschisis Underway

The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in Bethesda, Maryland.

03/13/15 5:38 am